Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease

Abstract. During the period February 1997 to April 2000, 15 patients with clinical symptoms of Creutzfeldt-Jakob disease (CJD) were referred to Uppsala University PET Centre. Positron emission tomography (PET) was performed to detect characteristic signs of the disease, e.g. neuronal death and/or astrocytosis in the brain. The examinations were performed in one session starting with oxygen-15 labelled water scan to measure regional cerebral blood flow, followed by imaging with the monoamine oxidase B inhibitor N-[11C-methyl]-L-deuterodeprenyl (DED) to assess astrocytosis in the brain and finally imaging with fluorine-18 2-fluorodeoxyglucose (FDG) to assess regional cerebral glucose metabolism (rCMRglu). Nine of the patients fulfilled the clinical criteria of probable CJD. In eight of them, FDG and DED imaging revealed, in comparison with normal controls, a typical pattern characterized by a pronounced regional decrease (<2SD) in glucose brain metabolism, indicative of neuronal dysfunction; this was accompanied by a similar increase (>2SD) in DED binding, indicating astrocytosis. These changes were most pronounced in the cerebellum and the frontal, occipital and parietal cortices, whereas the pons, the thalamus and the putamen were less affected and the temporal cortex appeared unaffected. The cerebral blood flow showed a pattern similar to that observed with FDG. In the ninth patient, analysis with DED was not possible. The diagnosis of definite CJD according to international consensus criteria was confirmed in six of these patients. In one patient with probable CJD, protease-resistant prion protein (PrPres) could not be demonstrated. In two patients with probable CJD, autopsy was not allowed. Computed tomography and magnetic resonance imaging, performed in four and seven of these nine patients respectively, showed unspecific, mainly atrophic changes. In six other patients, the PET examinations gave a different pattern. In three of them, high rCMRglu was noticed in parts of the brain, particularly in the temporal lobes and basal ganglia, which could suggest encephalitis. One of the patients had Sjögren's syndrome, one had paraneoplastic limbic encephalitis and the third recovered spontaneously. In the other three patients, the DED binding was normal despite a hypometabolic glucose pattern. In conclusion, the PET findings obtained using DED and FDG paralleled neuropathological findings indicating neuronal dysfunction and astrocytosis, changes that are found in CJD.

[1]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[2]  H. Kimura,et al.  Expression of monoamine oxidase B activity in astrocytes of senile plaques , 2004, Acta Neuropathologica.

[3]  N. Harada,et al.  Cholinergic Neuronal Modulation Alters Dopamine D2Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain , 2000, The Journal of Neuroscience.

[4]  J. Provenzale,et al.  Limbic encephalitis: comparison of FDG PET and MR imaging findings. , 1998, AJR. American journal of roentgenology.

[5]  M. Bergström,et al.  Temporal lobe epilepsy visualized with PET with 11 C‐L‐deuterium‐deprenyl – analysis of kinetic data , 1998, Acta neurologica Scandinavica.

[6]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[7]  C. Halldin,et al.  Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl , 1991, Brain Research.

[8]  P Brown,et al.  Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects , 1999, Annals of neurology.

[9]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[10]  S. Galetta,et al.  The Heidenhain Variant of Creutzfeldt–Jakob Disease: Clinical, Pathologic, and Neuroimaging Findings , 2001, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[11]  Louis Sokoloff,et al.  The [ 14 C]Deoxyglucose Method for Measurement of Local Cerebral Glucose Utilization , 1989 .

[12]  S. Prusiner,et al.  Bitemporal hypometabolism in Creutzfeldt-Jakob disease measured by positron emission tomography with [18F]-2-fluorodeoxyglucose. , 1984, Journal of computer assisted tomography.

[13]  H. Budka,et al.  Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.

[14]  Nobuko Mataga,et al.  Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey , 1994, Brain Research.

[15]  S. Holte,et al.  A preliminary evaluation of the scanditronix PC2048-15B brain scanner , 2004, European Journal of Nuclear Medicine.

[16]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  S. Gultekin,et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. , 2000, Brain : a journal of neurology.

[18]  J. Y. Kao,et al.  Cerebral metabolism during propofol anesthesia in humans studied with positron emission tomography. , 1995 .

[19]  M. Mintun,et al.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.

[21]  A. Luxen,et al.  Positron emission tomography and histopathology in Creutzfeldt‐Jakob disease , 1993, Neurology.

[22]  J. Ironside,et al.  Use of 14–3–3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[23]  C. Plets,et al.  Effect of Propofol on Cerebral Circulation and Autoregulation in the Baboon , 1990, Anesthesia and analgesia.

[24]  A. Colchester,et al.  MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. , 2001, Clinical radiology.

[25]  F. Brett,et al.  The "Pulvinar" sign in variant Creutzfeldt-Jakob disease. , 2000, AJR. American journal of roentgenology.

[26]  A. Vandesteene,et al.  Effect of propofol on cerebral blood flow and metabolism in man , 1988, Anaesthesia.

[27]  S. Raja,et al.  Sequential Positron Emission Tomographic Evaluations of Brain Metabolism in Acute Herpes Encephalitis , 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[28]  L. Thurfjell,et al.  Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. , 1997, Journal of computer assisted tomography.

[29]  R. Kessler,et al.  Limbic encephalitis and hyperactive foci on PET scan , 1999, Seizure.

[30]  S. Aquilonius,et al.  Monoamine oxidase‐B in astrocytes , 1993, Glia.

[31]  J. Y. Kao,et al.  Cerebral Metabolism during Propofol Anesthesia in Humans Studied with Positron Emission Tomography , 1995, Anesthesiology.

[32]  M. Matoba,et al.  Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. , 2001, Journal of computer assisted tomography.

[33]  D. Mathews,et al.  Quantitative Cerebral Blood Flow Imaging in a Patient with the Heidenhain Variant of Creutzfeldt-Jakob Disease , 2001, Clinical Nuclear Medicine.

[34]  E. Nitzsche,et al.  Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus , 2000, Lupus.